Normalization of B cell counts and subpopulations after antiretroviral therapy in chronic HIV disease.
about
The role of interleukin-21 in HIV infectionCo-evolution of a broadly neutralizing HIV-1 antibody and founder virusPremature B-cell senescence as a consequence of chronic immune activation.Increased Risk of Group B Streptococcus Invasive Infection in HIV-Exposed but Uninfected Infants: A Review of the Evidence and Possible MechanismsTransfer of Maternal Antimicrobial Immunity to HIV-Exposed Uninfected NewbornsImmune activation alters cellular and humoral responses to yellow fever 17D vaccineCD27(-) B-cells produce class switched and somatically hyper-mutated antibodies during chronic HIV-1 infectionIgM(+) memory B cell expression predicts HIV-associated cryptococcosis status.Characterising B cell numbers and memory B cells in HIV infected and uninfected Malawian adults.Virologic and immunologic correlates with the magnitude of antibody responses to the hepatitis A vaccine in HIV-infected children on highly active antiretroviral treatmentThe effectiveness of pneumococcal polysaccharide vaccination in HIV-infected adults: a systematic review.Impaired generation of hepatitis B virus-specific memory B cells in HIV infected individuals following vaccinationAntibody-secreting B cells in HIV infection.Collapse of the CD27+ B-cell compartment associated with systemic plasmacytosis in patients with advanced melanoma and other cancersOlder age is associated with peripheral blood expansion of naïve B cells in HIV-infected subjects on antiretroviral therapy.The impact of B-cell perturbations on pneumococcal conjugate vaccine response in HIV-infected adultsB cells in early and chronic HIV infection: evidence for preservation of immune function associated with early initiation of antiretroviral therapy.Immunologic basis for revaccination of HIV-infected children receiving HAART.B cells in HIV infection and diseaseHIV-associated lymphoma in the era of combination antiretroviral therapy: shifting the immunological landscapeImpaired antibody response to influenza vaccine in HIV-infected and uninfected aging women is associated with immune activation and inflammation.IgM Repertoire Biodiversity is Reduced in HIV-1 Infection and Systemic Lupus Erythematosus.Broadly cross-neutralizing antibodies in HIV-1 patients with undetectable viremiaIL-10-producing B cells are induced early in HIV-1 infection and suppress HIV-1-specific T cell responses.Bone marrow plasma cells are a primary source of serum HIV-1-specific antibodies in chronically infected individualsUpregulation of IL-21 receptor on B cells and IL-21 secretion distinguishes novel 2009 H1N1 vaccine responders from nonresponders among HIV-infected persons on combination antiretroviral therapy.Response to Pneumococcal Polysaccharide Vaccination in Newly Diagnosed HIV-Positive IndividualsInnate immune defects correlate with failure of antibody responses to H1N1/09 vaccine in HIV-infected patientsDelayed reconstitution of B cell immunity to pneumococcus in HIV-infected Malawian children on antiretroviral therapy.How can HIV-type-1-Env immunogenicity be improved to facilitate antibody-based vaccine development?Quantitative and Qualitative Antibody Responses to Immunization With the Pneumococcal Polysaccharide Vaccine in HIV-Infected Patients After Initiation of Antiretroviral Treatment: Results From a Randomized Clinical Trial.Emergence of exhausted B cells in asymptomatic HIV-1-infected patients naïve for HAART is related to reduced immune surveillance.Control of Viremia Enables Acquisition of Resting Memory B Cells with Age and Normalization of Activated B Cell Phenotypes in HIV-Infected ChildrenSuboptimal immune reconstitution in vertically HIV infected children: a view on how HIV replication and timing of HAART initiation can impact on T and B-cell compartmentReduced Number of Transitional and Naive B Cells in Addition to Decreased BAFF Levels in Response to the T Cell Independent Immunogen Pneumovax®23B-lymphocyte dysfunction in chronic HIV-1 infection does not prevent cross-clade neutralization breadth.Antiretroviral naive and treated patients: Discrepancies of B cell subsets during the natural course of human immunodeficiency virus type 1 infectionAdvances in human B cell phenotypic profiling.Longitudinal dynamics of the HIV-specific B cell response during intermittent treatment of primary HIV infectionAlterations in serotype-specific B cell responses to the 13-valent pneumococcal conjugate vaccine in aging HIV-infected adults.
P2860
Q27004704-2FDF66B3-F645-47DA-B0FB-E74A0D821955Q27644501-EB5E9139-133C-4C2B-882A-80C51261D741Q27693281-B65CDA07-3B5A-4D9D-9B93-0556C1099D08Q28067423-E0E3713F-A8A1-447F-B8C0-3DEE9E2B8F57Q28070259-9404C4F1-4AC4-4B8A-939E-B798EE58A8D0Q28388716-55CE2060-50F2-44E5-8AD2-F365F5BDC8F7Q33438469-16E53CF4-6516-409E-B3C4-4AFED312EE4CQ33585837-53F74216-765C-4FF0-8E11-AA0327AFE9B3Q33699375-FEF2BE49-1443-451C-A557-0F9BE7C8A49AQ33720842-B20BAF96-2FE6-43F6-94DE-1543384328E8Q33741026-B923B6AE-D454-428F-A30E-73941B45C3E2Q33820427-C3D0F6F6-F12D-45A4-8D46-85F8D2D753C0Q33914185-00E26107-7128-4BD7-A495-B870C105F86CQ33959343-11DDFEDF-6E57-45DB-8CBE-1CECB73431DAQ34160176-24466E5A-0744-4216-B779-2608EB14C98BQ34364783-D2F25FB2-BB97-4650-964C-BA88F7C57DD9Q34541705-A48B84BD-9963-47A9-8DE9-F7FD8061D5C0Q34575987-451B585E-2CA8-4AE4-8F08-B6501B953AD5Q34605780-3AC4AD30-EFBB-4DB8-B380-FF15DCD35AA9Q34671009-56EA683D-0263-41B9-B76D-6259A4CDECFBQ35043898-6F80A6EF-1EA6-4CD5-A6AC-69E2E973BF0FQ35057901-7AD84944-3FEF-4684-8C8C-0C1F21D76683Q35077039-BB2EA7A8-E2CF-4E08-936E-72F9A557F349Q35106912-25A01988-9E79-49E6-BED4-B5DE2941E0D7Q35164477-5CC4C81A-EB95-4D8A-AADA-06FA4B90B976Q35207950-C24D975C-2575-4F6C-BBE1-C13425D32989Q35511216-56EF41AE-5235-4C2F-ABA9-109750A8B610Q35589557-A3DCC9FC-A0E9-4E1E-86D5-A31B4CB4715BQ35635685-FBEA1E14-ECA9-4EA5-9526-D630FD3B4F68Q35653703-4E2ECBF8-8662-4972-8578-5B3C883172EDQ35753485-5B57932D-2E39-40C8-9160-1ADD89D01919Q35830092-984D612C-A1FE-4D80-99C0-E346A8BC6BD1Q35861977-133DCEF2-76AA-44BA-A68C-2761F80063BFQ35895763-9B50D1C6-CA98-4454-9295-61447A3C0C2BQ35974921-8DE8E384-FBFE-4F83-80DD-E51F13BEDA7EQ36171833-5E423C00-7242-4217-8AD2-B83698AE26D1Q36202092-D2F9EF93-480D-4FE7-835A-128FDE09439DQ36307080-5C705A85-7506-4008-8AE4-B8D64D9BBE7DQ36309003-3B082291-9F98-4FCA-8BED-DF8C25FFAE0FQ36463700-B86A5287-61EA-408E-B8AB-87D83B8A225B
P2860
Normalization of B cell counts and subpopulations after antiretroviral therapy in chronic HIV disease.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Normalization of B cell counts ...... herapy in chronic HIV disease.
@en
Normalization of B cell counts ...... herapy in chronic HIV disease.
@nl
type
label
Normalization of B cell counts ...... herapy in chronic HIV disease.
@en
Normalization of B cell counts ...... herapy in chronic HIV disease.
@nl
prefLabel
Normalization of B cell counts ...... herapy in chronic HIV disease.
@en
Normalization of B cell counts ...... herapy in chronic HIV disease.
@nl
P2093
P2860
P50
P356
P1476
Normalization of B cell counts ...... herapy in chronic HIV disease.
@en
P2093
Angela C Dipoto
Angela Malaspina
Gregg Roby
Joann M Mican
Marie A O'Shea
Michael A Proschan
P2860
P304
P356
10.1086/526789
P407
P577
2008-02-01T00:00:00Z